The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its legacy within the broader market now triggers questions about potential yields . Generic versions are undercutting exclusivity , leading to concerns that investing in companies closely tied to Viagra's once-dominant position could be a problematic